The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
The Chosun Ilbo on MSN
South Korea’s distinctive IV drip culture
I once turned back from visiting a nearby internal medicine clinic during lunchtime due to a cold. The waiting room was ...
Korea JoongAng Daily on MSN
Jun Hyun-moo's agency explains video of him with IV drip is from 2016, not related to 'injection auntie' controversy
TV personality Jun Hyun-moo’s agency denied allegations Friday that Jun received illegal medical treatment after a clip from ...
FDA approves Johnson & Johnson's Rybrevant Faspro for EGFR lung cancer and expands TRUFILL use for chronic subdural hematoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback